A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency (GHD)

This is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.

开始日期2025-08-01

申办/合作机构

Lumos Pharma, Inc.

NCT05796440

/ Enrolling by invitation临床2期

An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children With Idiopathic Growth Hormone Deficiency

This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.

开始日期2023-08-01

申办/合作机构

Lumos Pharma, Inc.

NCT05364684

/ Completed临床2期IIT

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: a Pilot Study

Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1H-MRS).

开始日期2022-08-10

申办/合作机构

The General Hospital Corp.

100 项与伊布莫仑相关的临床结果

登录后查看更多信息

100 项与伊布莫仑相关的转化医学

登录后查看更多信息

100 项与伊布莫仑相关的专利（医药）

登录后查看更多信息

217

项与伊布莫仑相关的文献（医药）

2025-04-01·Drug Testing and Analysis

Elucidating important factors and corresponding method optimization for sensitive detection of small peptide drugs in human urine by solid‐phase extraction and UPLC‐HRMS: The influence of MS scan modes, protein precipitants, and ammonium formate

Article

作者: Liu, Yunxi ; Chang, Wei ; He, Genye ; Ma, Congcong ; Zhang, Yufeng ; Liu, Lu ; Dong, Tianyu ; Wang, Zhanliang ; Yan, Kuan

Abstract:

Small peptide hormones are widely used in sports as performance‐enhancing substances, making it crucial to develop sensitive analytical methods for their detection in doping control analysis. Various factors significantly affect analytical sensitivity, such as the selection of ultra‐performance liquid chromatography (UPLC) mobile phase, high‐resolution mass spectrometry (HRMS) scanning modes, and extraction solvents for pretreatment. Herein, comparative study approach was utilized to investigate the sensitivity of each peptide analyte under both full scan and parallel reaction monitoring (PRM) modes of HRMS and assess the effects of some protein precipitants as a part of extraction solvents on solid‐phase extraction (SPE). The results showed that full scan should be selected as the primary scan mode of HRMS, and the combination with PRM mode could effectively compensate for the limitations of full scan, and the addition of protein precipitants would adversely affect the detection of certain small peptide analytes. Meanwhile, influences of ammonium formate in reverse UPLC mobile phase on the charge state distribution of small peptides were investigated and elucidated. Based on these findings, a sensitive and reliable UPLC‐HRMS analytical method combining full scan and PRM mode was validated for screening and confirmation of 63 small peptide analytes after SPE, with limits of detection (LODs) ranging between 0.010 and 0.473 ng/ml and limits of identification (LOIs) ranging between 0.015 and 1.512 ng/ml. Additionally, suggestions were provided for the detection of [Arg8]‐vasopressin, dermorphin, and its analogues.

2025-03-27·JOURNAL OF MEDICINAL CHEMISTRY

Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency

Article

作者: Yang, Fanglong ; Jin, Lei ; Liu, Meng ; Wang, Siqin ; Jia, Xiangyu ; Zhao, Sheng ; Xia, Yuanfeng ; Lu, Biao ; Xu, Hang

Recombinant human growth hormone (rhGH) is a well-established treatment for children with growth deficiencies worldwide. However, its requirement for subcutaneous administration limits convenience compared to that of oral therapies. Starting from capromorelin, we designed, synthesized, and characterized a novel orally active GHSR-1a agonist, compound 4b (hGHSR-1a EC₅₀ = 0.49 nM), which effectively stimulates endogenous GH release in rats at oral doses as low as 0.1 mg/kg─100-fold more potent than ibutamoren (10 mg/kg). Notably, 10 day oral administration of 4b increased body weight and length in 4-week-old rats. To date, comprehensive preclinical studies on oral agents for short stature remain limited, and existing GHSR-1a agonists lack approval for this indication. Compound 4b exhibited superior pharmacokinetic exposure in dogs (oral bioavailability: 43.6%; half-life: 1.2 h) relative to other species. This study details the optimization of 4b, which demonstrates a promising pharmacological profile for clinical translation as a growth hormone replacement therapy.

2025-02-05·ENDOCRINOLOGY

Intranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice

Article

作者: Stoltenborg, Iris ; Schéle, Erik ; Poelman, Renée ; Dickson, Suzanne L ; Le May, Marie V

Abstract:

Ghrelin, the endogenous ligand of the growth hormone secretagogue receptor (GHSR), promotes food intake and other feeding behaviors, and stimulates growth hormone (GH) release from the pituitary. Growth hormone secretagogues (GHS), such as GHRP-6 and MK-0677, are synthetic GHSR ligands that activate orexigenic neuropeptide Y neurons that coexpress agouti-related peptide (AgRP) in the arcuate nucleus of the hypothalamus when administered systemically. Systemic GHRP-6 also stimulates GH release in humans and rats. Thus, GHS and ghrelin have therapeutic relevance in patients who could benefit from its orexigenic and/or GH-releasing effects. This study examined whether intranasal delivery of ghrelin, GHRP-6, or MK-0677 engages the brain ghrelin signaling system.Effective compounds and doses were selected based on increased food intake after intranasal application in mice. Only GHRP-6 (5 mg/kg) increased food intake without adverse effects, prompting detailed analysis of meal patterns, neuronal activation in the arcuate nucleus (via Fos mapping) and neurochemical identification of c-fos messenger RNA (mRNA)-expressing neurons using RNAscope. We also assessed the effect of intranasal GHRP-6 on serum GH levels.Intranasal GHRP-6 increased food intake by increasing meal frequency and size. Fos expression in the arcuate nucleus was higher in GHRP-6–treated mice than in saline controls. When examining the neurochemical identity of c-fos-mRNA–expressing neurons, we found coexpression with 63.5 ± 1.9% Ghsr mRNA, 79 ± 6.8% Agrp mRNA, and 11.4 ± 2.5% Ghrh mRNA, demonstrating GHRP-6's ability to engage arcuate nucleus neurons involved in food intake and GH release. Additionally, intranasal GHRP-6 elevated GH serum levels. These findings suggest that intranasal GHRP-6, but not ghrelin or MK-0677, can engage the brain ghrelin signaling system.

项与伊布莫仑相关的新闻（医药）

2024-12-16

·GlobeNewswire-Health Care

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma

Dec. 12, 2024 -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right (“CVR”) for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events relating to the level of annual global net revenue of LUM-201 up to the year 2037, different transactions involving Lumos Pharma or its assets that occur within 18 months of closing or certain sales, license or similar revenue-generating agreements entered into within 18 months of closing and that are related to Lumos Pharma’s legacy products other than LUM-201. There can be no assurance any payments will be made with respect to the CVRs. The purchase price of $4.25 per share represents a total equity value of approximately $38 million, a premium of 7.6% to Lumos Pharma’s closing share price of $3.95 on October 22, 2024, and a premium of 10.5% to Lumos Pharma’s 30-trading-day volume weighted average price as of October 22, 2024. The tender offer expired one minute after 11:59pm Eastern Time on December 11, 2024. As of the expiration of the tender offer, 6,544,417 shares of Lumos Pharma common stock were validly tendered into and not withdrawn pursuant to the offer, representing approximately 75.62% of Lumos Pharma’s outstanding shares. All conditions of the tender offer were satisfied or waived and all shares validly tendered and not validly withdrawn were accepted for payment and DPV or its affiliates is promptly paying for all such tendered shares in accordance with the terms of the tender offer. As a result of its acceptance of the shares tendered in the tender offer, DPV and its affiliates acquired a sufficient number of shares of Lumos Pharma’s common stock to close the merger without the affirmative vote of Lumos Pharma’s other stockholders, pursuant to Section 251(h) of the Delaware General Corporation Law. As such, the merger was completed today, December 12, 2024. With the successful completion of the merger, Lumos Pharma will operate as a standalone business of DPV from its current headquarters in Austin, Texas. Each outstanding share of Lumos Pharma’s common stock that was not validly tendered in the tender offer (other than shares owned by affiliates of DPV, Lumos Pharma (as treasury stock) or by any stockholder of Lumos Pharma who is entitled to and properly demanded and perfected appraisal of such shares pursuant to, and complies in all respects with, the applicable provisions of Delaware law) was cancelled and converted into the right to receive (i) an amount in cash equal to $4.25 per share, without interest and less applicable tax withholding and (ii) one CVR. In addition, the common stock of Lumos Pharma ceased to trade on NASDAQ and a notice of delisting with respect to shares of Lumos Pharma is expected to be filed promptly by NASDAQ. Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/. Double Point Ventures is a venture capital fund dedicated to empowering healthcare and life sciences companies in developing groundbreaking drugs, medical devices, and diagnostics, with a mission to enhance patient outcomes and drive meaningful advancements in health. The content above comes from the network. if any infringement, please contact us to modify.

孤儿药并购

2024-11-21

·GlobeNewswire-Health Care

Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action

AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. “The new analyses and updated data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ESPE this week demonstrate sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, as well as the correlation of LUM-201’s pulsatile mechanism of action (MOA) to growth,” said John C. McKew, PhD, President and Chief Scientific Officer of Lumos Pharma. “We are encouraged by these data and look forward to advancing oral LUM-201 in a Phase 3 clinical trial in moderate PGHD next year.” In the oral presentation of Abstract FC7.6 on Sunday, November 17th, entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al) [link], the investigator reviewed updated combined data from the Phase 2 OraGrowtH210 and OraGrowtH212 Trials out to 24 months following treatment with LUM-201. Results showed that at six months on LUM-201, a significant increase over baseline in Annualized Height Velocity (AHV) was observed for the combined 1.6 and 3.2 mg/kg/day doses. At baseline, AHV was 4.6 cm/yr for 37 subjects for which baseline data were available vs 7.8 cm/yr at 6 months on LUM-201 for 66 subjects.Results also showed that growth rates on oral LUM-201 (combined 1.6 and 3.2 mg/kg dose cohorts) were sustained out to 24 months with AHVs of 7.3 (N=65), 7.5 (N=36), and 7.3 (N=20) cm/yr at 12, 18, and 24 months, respectively [graphic below]. Combined results also demonstrated significant increases in IGF-1 and IGFBP-3 levels from baseline out to 24 months, with IGF-1 increasing from 13.1 (baseline) to 25.5 (12 months) to 29.2 (24 months) nmol/L and IGFBP-3 increasing from 133.5 (baseline) to 179.6 (12 months) to 186.2 (24 months) nmol/L.Conclusions: LUM-201 shows a significant increase in AHV at 6 months, and the effect continues with a minimal decrease in AHV through 24 months. Compared to historical rhGH (KIGS)1, LUM-201 has a smaller drop in AHV from 12 months to 24 months. LUM-201 significantly increases IGF-1 and IGFBP-3 levels at 12 months which continues to 24 months. A favorable investigational safety profile has been observed to date. In the late-breaking oral presentation of Abstract FC15.2 on Monday, November 18th, entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al) [link], the investigator reviewed data from OraGrowtH212 demonstrating the relationship between pulsatile GH profiles and both the growth and IGF-1 responses to LUM-201 treatment. Data from 22 prepubertal children with moderate PGHD from the OraGrowtH212 Trial were evaluated with subjects grouped into tertiles based on 6-month annualized height velocity (AHV).Pulsatile growth hormone (GH) pulse assessments at baseline and at 6 months (M6) were characterized using 1) Approximate Entropy (ApEn, scale 0-1) examining degree of orderliness over the whole profile and 2) Functional Principal Component Analysis (FPCA) identifying where within the 12-hour profile, divided into 4-hour periods, the dominant variation occurred.Results of 6-month treatment with LUM-201: Pulsatile GH secretion, ApEn, IGF-1 SDS and IGFBP-3 SDS increased from baseline to M6.Greater M6 AHV was associated with an earlier periodicity of augmented pulsatile GH secretion [graphic below]. Conclusion: Both amount and pattern of GH secretion are important for growth and IGF-1 responses to LUM-201. 1 Ranke et al., 2010 – Pfizer KIGS database rhGH treated cohort of moderate prepubertal GHD children. About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. A law that, in part, gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct. We are passionate about our business - including LUM-201 and the potential it may have to help patients in the clinic. This passion feeds our optimism that our efforts will be successful and bring about meaningful change for patients. Please keep in mind that actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. We have attempted to identify forward-looking statements by using words such as “projected,” “upcoming,” “will," “would,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” “imminent,” and similar references to future periods or the negative of these terms. Not all forward-looking statements contain these identifying words. Examples of forward-looking statements include, among others, statements we make regarding the advancement of oral LUM-201 to Phase 3, the potential for LUM-201 to be the first oral therapeutic for PGHD, and any other statements other than statements of historical fact. We wish we were able to predict the future with 100% accuracy, but that just is not possible. Our forward-looking statements are neither historical facts nor assurances of future performance. You should not rely on any of these forward-looking statements and, to help you make your own risk determinations, we have provided an extensive discussion of risks that could cause actual results to differ materially from our forward-looking statements including risks related to the timing and ability of Lumos Pharma to structure our Phase 3 trial in an effective and timely manner, the ability to initiate and advance a pivotal Phase 3 trial, as well as advance our clinical and corporate strategy in general, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to successfully develop our product candidate, the effects of pandemics, other widespread health problems or military conflicts including the Ukraine-Russia conflict and the Middle East conflict and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements including information in the "Risk Factors" section and elsewhere in Lumos Pharma’s Quarterly Report on Form 10-Q for the period ended September 30, 2024, as well as other subsequent reports filed with the SEC. All of these documents are available on our website. Before making any decisions concerning our stock, you should read and understand those documents. We anticipate that subsequent events and developments will cause our views to change. We may choose to update these forward-looking statements at some point in the future, however, we disclaim any obligation to do so. As a result, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Investor & Media Contact: Lisa MillerLumos Pharma Investor Relations512-792-5454ir@lumos-pharma.com Photos accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/f1abdd2c-307b-47bb-8cc9-3c555fe00c85https://www.globenewswire.com/NewsRoom/AttachmentNg/b168603b-a009-4bce-a4d1-94367f1568ec Source: Lumos Pharma, Inc.

临床结果临床2期孤儿药临床1期

2024-10-30

·GlobeNewswire-Health Care

Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK. Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin, Poland, and on Monday, November 18th, by Peter E. Clayton, MD, University of Manchester, Manchester, UK, respectively. LUM-201 Oral Abstract Presentations: Sunday, November 17th – Session: Free Communications 7: GH and IGFs – 10:50AM Local Time FC7.6 Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al) Monday, November 18th – Session: Free Communications 15: Late Breaking – 9:40AM Local Time FC15.2 Abstract entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al) About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/. Investor & Media Contact: Lisa MillerLumos Pharma Investor Relations512-792-5454ir@lumos-pharma.com Source: Lumos Pharma, Inc.

临床2期孤儿药

100 项与伊布莫仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04491	伊布莫仑	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
生长激素缺乏症	临床3期	-	Lumos Pharma, Inc.	2025-08-01
骨折	临床3期	美国	Merck GmbH	-
绝经期后骨质疏松	临床3期	美国	Merck GmbH	-
非酒精性脂肪肝	临床2期	美国	The General Hospital Corp.	2022-08-10
非酒精性脂肪性肝炎	临床2期	美国	The General Hospital Corp.	2022-08-10
垂体性侏儒症	临床2期	智利	Lumos Pharma, Inc.	2021-06-01
慢性肾病	临床2期	美国	Merck Sharp & Dohme Corp.	2009-03-01
髋部骨折	临床2期	德国	Merck Sharp & Dohme Corp.	2005-09-01
髋部骨折	临床2期	挪威	Merck Sharp & Dohme Corp.	2005-09-01
髋部骨折	临床2期	西班牙	Merck Sharp & Dohme Corp.	2005-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04806854 \| NCT04614337 (OraGrowtH212, Corporate Publications \| GlobeNewswire) 人工标引	临床2期	生长激素缺乏症	66	LUM-201	顧醖製鑰獵獵糧製鬱窪(齋廠醖顧餘襯鏇鑰積鹹) = 夢醖築窪觸齋淵膚夢製衊窪構顧築範廠鏇衊築 (範願蓋獵艱築遞淵夢衊 ) 更多	积极	2024-11-17
OraGrowtH212 (ENDO2024)	临床2期	生长激素缺乏症 insulin-like growth factor-1 (IGF-1)	22	LUM-201 1.6 mg/kg/d	蓋簾衊構範膚鹽蓋蓋鹹(鹽顧築選廠網鹽範積鹹) = 糧製衊夢艱願鹽選淵選齋選廠衊憲積獵構膚遞 (廠範壓淵醖構糧積鑰獵 ) 更多	积极	2024-06-01
				LUM-201 3.2 mg/kg/d	蓋簾衊構範膚鹽蓋蓋鹹(鹽顧築選廠網鹽範積鹹) = 糧壓蓋夢積醖蓋糧願範齋選廠衊憲積獵構膚遞 (廠範壓淵醖構糧積鑰獵 ) 更多
NCT04614337 (OraGrowtH210, Corporate Publications) 人工标引	临床2期	生长激素缺乏症	-	LUM-201	構遞齋窪鹹願網獵鹹醖(夢糧範築憲憲夢窪鏇衊) = 簾膚淵窪壓顧鹽醖衊廠淵襯遞齋築窪獵願顧餘 (願鹹憲簾齋齋簾築願衊 ) 达到更多	积极	2023-11-07
NCT04806854 (OraGrowtH212, ENDO2023)	临床2期	生长激素缺乏症 IGF-1 \| GH	10	LUM-201 0.8 mg/kg	觸網糧壓鏇餘願艱餘襯(蓋範鬱餘簾願積積壓積) = 衊積壓餘鑰鏇積壓廠繭遞積蓋窪廠觸構觸糧範 (選積觸網願壓糧製遞獵, + 10.6)	积极	2023-10-05
				LUM-201 1.6 mg/kg	鬱繭鏇網願繭膚選構製(餘鬱鏇壓積願醖齋築鏇) = 顧顧糧襯網餘醖膚築蓋網網鏇積製淵窪鬱顧觸 (廠鹽憲繭鑰餘憲願選廠, + 0.65) 更多
OraGrowtH210 and OraGrowtH212 (ENDO2023)	临床2期	生长激素缺乏症 insulin-like growth factor-1 (IGF-1)	-	LUM-201 1.6 mg/kg/day	壓艱壓廠願齋積範窪獵(鬱鹽鏇齋廠夢鏇窪鑰獵) = 遞膚繭醖憲鹹齋廠構願廠鑰網顧鹹繭選齋鹽簾 (鑰窪繭襯製淵範淵遞範, 1.9)	积极	2023-10-05
				LUM-201 3.2 mg/kg/day	壓艱壓廠願齋積範窪獵(鬱鹽鏇齋廠夢鏇窪鑰獵) = 選夢鬱醖糧鬱餘淵願膚廠鑰網顧鹹繭選齋鹽簾 (鑰窪繭襯製淵範淵遞範, 1.5)
ESPE2023	N/A	生长激素缺乏症	15	LUM-201 1.6 mg/kg/day	簾襯積顧範築網鬱壓獵(廠壓餘鏇醖願繭衊製醖) = 製獵醖繭夢齋鹹顧壓鑰醖獵膚窪廠鹹積淵夢鹽 (淵膚製蓋餘壓繭憲衊願 )	-	2023-09-21
				LUM-201 3.2 mg/kg/day	簾襯積顧範築網鬱壓獵(廠壓餘鏇醖願繭衊製醖) = 廠窪範鏇觸膚齋鏇鏇製醖獵膚窪廠鹹積淵夢鹽 (淵膚製蓋餘壓繭憲衊願 )
NCT04806854 (OraGrowtH212, GlobeNewswire) 人工标引	临床2期	生长激素缺乏症	10	Ibutamoren Mesylate (1.6 mg/kg/day LUM-201)	選醖顧淵衊積積鹽遞鑰(獵蓋鑰觸齋繭鏇膚遞膚) = 蓋夢顧簾鏇鬱網築繭簾觸觸餘鬱衊窪觸鏇窪淵 (範膚簾齋憲淵蓋糧艱膚 ) 更多	积极	2022-11-14
				Ibutamoren Mesylate (3.2 mg/kg/day LUM-201)	選醖顧淵衊積積鹽遞鑰(獵蓋鑰觸齋繭鏇膚遞膚) = 鏇艱選醖醖願蓋積艱遞觸觸餘鬱衊窪觸鏇窪淵 (範膚簾齋憲淵蓋糧艱膚 ) 更多
LUM-201 (ENDO2021)	N/A	生长激素缺乏症	68	LUM-201	選鬱獵廠簾獵膚範繭蓋(膚夢觸鹽築選觸簾鑰觸) = 壓糧築網鑰淵構夢衊鹽淵選艱顧願選憲築製窪 (製壓顧範構衊製鹽觸衊, 3.5 ~ 49)	积极	2021-05-03
				Standard GH Secretagogues (clonidine, arginine, L-dopa, glucagon, insulin)	選鬱獵廠簾獵膚範繭蓋(膚夢觸鹽築選觸簾鑰觸) = 鹽襯獵餘簾淵淵糧艱夢淵選艱顧願選憲築製窪 (製壓顧範構衊製鹽觸衊, 1.8 ~ 7.6)
MP85-02 (AUA2018)	N/A	多发性内分泌瘤病	-	Ibutamoren	遞艱齋鹹鬱壓壓齋糧選(淵願壓構膚積鹽積窪淵) = 醖選願範廠餘壓構衊願餘範遞願艱製鬱餘繭醖 (構鏇範鬱齋廠遞鹽築窪 ) 更多	-	2018-04-01
NCT00395291 (Pubmed) 人工标引	N/A	-	26	MK-0677	築淵觸憲網醖鏇醖襯願(遞蓋憲壓製觸獵糧獵艱) = 窪選壓膚鹽膚蓋淵簾網觸鬱糧襯壓襯鑰鏇淵顧 (窪鬱獵廠衊積觸製壓觸, 1.48 ~ 2.10)	积极	2018-03-01
				Placebo	築淵觸憲網醖鏇醖襯願(遞蓋憲壓製觸獵糧獵艱) = 膚襯糧簾範遞範遞築憲觸鬱糧襯壓襯鑰鏇淵顧 (窪鬱獵廠衊積觸製壓觸, 0.89 ~ 1.27)